MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

Core Viewpoint - MediPharm Labs Corp. has signed a definitive supply agreement with Remidose Aerosols Inc. to ship GMP-certified medicinal cannabis products to Costa Rica, enhancing its commitment to support medical patients in the region and expand international access to quality cannabis solutions [1][2]. Company Overview - MediPharm Labs specializes in precision-based cannabinoids and operates a GMP-certified facility for the development and manufacture of pharmaceutical-quality cannabis products [6]. - The company has a strong focus on research-driven methodologies and advanced technology for producing pure and precision-dosed cannabis products [6]. - In 2021, MediPharm Labs became the only company in North America to hold a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [7]. - The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm's reach to medical patients in Canada, Australia, and Germany [8]. Market Context - Costa Rica's medical cannabis market opened for regulated sales in June 2025 and is projected to exceed USD 35 million annually, driven by strong patient demand and a comprehensive regulatory framework [2]. - The partnership with Remidose LATAM aims to provide high-quality, GMP-certified cannabis products to meet the needs of patients in Costa Rica [4]. Agreement Details - Under the agreement, MediPharm Labs will supply a variety of GMP-certified cannabis products, including oils, tinctures, metered dose inhalers, and dried flower to Remidose LATAM [3]. - Remidose LATAM is fully licensed by Costa Rican health authorities to import medicinal cannabis products, ensuring compliance with local regulations [4][5].